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Background: Identifying heart failure patients most likely to suffer poor outcomes is an essential part of delivering
interventions to those most likely to benefit. We sought a comprehensive account of heart failure events and their
cumulative economic burden by examining patient characteristics that predict increased cost or poor outcomes.
Methods: We collected electronic medical data from members of a large HMO who had a heart failure diagnosis
and an echocardiogram from 1999–2004, and followed them for one year. We examined the role of demographics,
clinical and laboratory findings, comorbid disease and whether the heart failure was incident, as well as mortality.
We used regression methods appropriate for censored cost data.
Results: Of the 4,696 patients, 8% were incident. Several diseases were associated with significantly higher and
economically relevant cost changes, including atrial fibrillation (15% higher), coronary artery disease (14% higher),
chronic lung disease (29% higher), depression (36% higher), diabetes (38% higher) and hyperlipidemia (21% higher).
Some factors were associated with costs in a counterintuitive fashion (i.e. lower costs in the presence of the factor)
including age, ejection fraction and anemia. But anemia and ejection fraction were also associated with a higher
death rate.
Conclusions: Close control of factors that are independently associated with higher cost or poor outcomes may
be important for disease management. Analysis of costs in a disease like heart failure that has a high death rate
underscores the need for economic methods to consider how mortality should best be considered in
costing studies.Background
Heart failure prevalence is estimated at 1% to 2% in
the US, with an annual cost (direct and indirect) of over
$33 billion [1]. From 1994 to 2004 deaths from heart
failure increased by 28%, while the overall death rate
decreased by 2% [1]. The annual cost of heart failure to
insurers has recently been estimated to be greater than
$8,000 per person per year [2], with cost estimates of
heart failure related admissions estimated at greater than
$12,000 [3].
Recent systematic reviews have highlighted the utility
of disease management programs in heart failure, with
reductions in heart failure hospitalizations of 27% (95%
CI, 18% to 34%) [4]. Identifying heart failure patients
who are most likely to suffer poor outcomes is an essen-
tial part of delivering interventions to those most likely* Correspondence: David.h.smith@kpchr.org
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reproduction in any medium, provided the orto benefit. To date, most clinical prediction efforts in
heart failure risk stratification have been undertaken
among clinical trial populations and recently hospita-
lized patients. These studies have sought to inform clin-
ical decision-making, for example, about whether
patients presenting to the emergency department with a
heart failure exacerbation should be admitted to the hos-
pital or can be safely discharged to home [5]. These
studies have included prediction of important short-
term (e.g. 30 day) outcomes in heart failure including all
cause mortality, and expensive events like inpatient mor-
tality and inpatient complications [6,7]. But we sought a
more comprehensive account of heart failure's events
and their cumulative economic burden among a
community-based population, so we predict overall
expenditures. By attaching a dollar value to units of
healthcare resource use, analysts can predict one com-
prehensive outcome, cost. Combining utilization may be
especially meaningful in a disease like heart failure
where the burden is not easily described with simpletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on capturing all of the ways that outcomes appear.
These estimates may also be useful for modeling the
cost-effectiveness of heart failure interventions.
Our analyses predict overall cost and allow us to
examine the role of demographics, clinical findings, and
comorbid disease in a way that can help clinicians and
those responsible for population management focus their
service provision. Our study uses data on a cohort of
heart failure patients with near complete capture of clin-
ical events. Knowing how strongly factors contribute to
this comprehensive reflection of heart failure’s burden
may yield new insights into potential strategies for bur-
den reduction. These data can also be useful for health
service expenditure planning, and for understanding
how effective treatments might change costs of care.
Since we focus on patients in the community setting our
study is relevant to the larger set of heart failure
patients. Because others have noted that patients with
incident disease may differ in important ways from those
with prevalent disease [8], we also explored whether
costs differ by this attribute.
Methods
Setting
We used data from a non-profit group-model Health
Maintenance Organization (HMO) that provides fully
integrated health care to approximately 480,000 indivi-
duals in the Northwestern US to conduct this retrospect-
ive cohort study. The HMO has linked electronic
databases that we used to collect patient level informa-
tion on health care expenditure and utilization (including
inpatient and outpatient visits, laboratory results and
pharmacy utilization). Our study was approved by the
Research Subjects Protection Office at Kaiser Perma-




Patients included in the study were HMO members
20 years and older who had an echocardiogram and a
diagnosis of heart failure between 1999 and 2004; they
were followed for up to one year post echocardiogram
(or until April 1, 2005, death, or disenrollment from the
health plan, whichever came first). The patient’s first
echocardiogram, plus 30 days, served as the index date
for all data collection. We allowed 30 days post-
echocardiogram so that we could identify incident
patients whose echocardiogram was part of their heart
failure diagnostic work-up. All patients had at least one
year of membership (and prescription benefit coverage)
prior to their index date and had between one and three
years of baseline data from which baseline covariatesand heart failure diagnoses were extracted. Patients had
an inpatient or outpatient diagnosis of heart failure
(ICD-9 428) during the baseline period; that diagnostic
code has a predictive value positive of 82% for heart fail-
ure [9], but may not be the same in our setting.
Variables
As has been done in other retrospective studies in heart
failure [10], we examined clinical findings and diagnoses
that are thought to be related to heart failure. The most
current baseline value (before the index date) was
extracted from the HMO’s electronic medical record (in-
cluding laboratory data, and inpatient or outpatient vis-
its, except where noted). Table 1 describes how we
defined clinical variables.
Costs of care
In the costing method we used [11], standard costs for
units of medical care (ie. office visits and direct hospital
service components) were identified from aggregate de-
partmental expenditures and administrative costs; other
indirect and joint costs were allocated to units of direct
costs. These standard unit costs were multiplied by
utilization volume to obtain total costs. The pharma-
ceutical prices approximated retail costs in the local
market. For care provided in non-HMO facilities, costs
are the amounts that the HMO paid to vendors. All
costs were adjusted to reflect 2005 prices. The expendi-
tures include nearly all the costs of acute inpatient and
outpatient care (fewer than 10% of members use an out-
of-plan service in any given year).
Statistical analysis
Using cost as a dependent variable requires special at-
tention to both its functional form (right skewness) and
to censoring. To address skewness we employed a nat-
ural log transformation, allowing us to use regression
models based on the assumption of normality of error
terms. This assumption was checked and verified with
residual plots. To deal with censoring, we used the
method as outlined by Baser and colleagues [12] wherein
costs are recorded as a panel (monthly) dataset and in-
verse proportional weighting is used to derive an un-
biased estimate of costs even if we have informative
censoring. Weights were derived using time-to-event
methods, where the event was censoring. Monthly costs
within a patient are correlated, and we investigated both
population-averaged models (using general estimating
equations (GEE)) and patient-specific models (using ran-
dom intercepts for patients) to account for this. In the
case of a linear model, these two approaches are equiva-
lent. However, GEE does not require the assumption of
compound symmetry (even as a working correlation
structure) as does the random intercepts model. This





Race Membership file and electronic medical
record (EMR)
BMI EMR (BMI; weight in kg/height in m2)
Smoking Status EMR
Clinical characteristics
Hypertension ICD-9 codes 401.xx – 405.xx, or systolic
>140 or diastolic >90
Hyperlipidemia ICD 9 code 272.x, or total cholesterol
>199mg/dL, or low density lipoprotein
>129mg/dL
Ischemic stroke ICD 9 codes: 433.xx, 434.xx, 436,
438.0-438.53, 438.8-438.82, 438.89, 438.9,
997.02
Transient ischemic attack ICD 9 codes: 435.xx
Hypothyroidism ICD 9 codes: 243, 244.xx
Chronic lung disease ICD 9 codes: 490, 491–491.21, 491.8,
491.9, 492.xx, 493.0x, 493.1x, 493.2x,
493.9x, 494.x, 495, 495.0, 495.2-495.9,
496, 518.1, 518.2
Aortic/mitral valvular disease ICD 9 codes: 395.xx, 424.0, 424.1,
746.3-746.6, 746.81, 394.xx, 396.xx
Depression ICD 9 codes: 296.2x-296.6x, 296.7, 296.8,
296.80, 296.82, 296.89, 300.4, 301.12,
309.1, 311
Atrial fibrillation or flutter ICD 9 codes: 427.3x
Diabetes Health plan diabetes registry
Coronary artery disease/
acute myocardial infarction
ICD 9 codes: 410.xx – 414.xx, excluding
414.10, 414.11, 414.19
Peripheral vascular disease ICD 9 codes: 250.7x, 440.xx, 443.81, 443.9
Left ventricular wall thickness echocardiogram
Ejection fraction echocardiogram
Laboratory characteristics
Renal function Outpatient laboratory values for serum
creatinine (glomerular filtration rate
estimated from MDRD equation)
BMI (Body mass index), EMR (electronic medical record), ICD-9 (International
Classification of Diseases, 9th revision, clinical modification), MDRD (4-variable
Modification of Diet in Renal Disease equation).
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sures data. For that reason, we preferred the GEE ap-
proach. We performed a Hausman test to help
determine whether the weighting was necessary. In our
analysis we noted there were no material differences in
the random versus fixed effects models and the Haus-
man test showed there was no statistically significant
difference between the weighted and unweighted regres-
sions; because of this we present only the unweighted,
pooled ordinary least squares (POLS) results. Standard
errors have been obtained using GEE with a working
correlation structure of independence. Our datasetconsisted of 12 monthly observations on total cost post
index date for all patients. The analysis was adjusted for
month by including dummy variables for month in the
regression models. Because costs are known after death,
we recorded monthly costs as zero after death; $1 was
added to any monthly cost of zero before taking the
logarithm. The above analyses were repeated, with re-
striction to those patients who survived the entire 12
months of follow-up. We present the results as the aver-
age monthly costs as a relative percent change from the
omitted group in the regression using the formula of
van Garderen and Shah [13] to obtain the exact un-
biased estimator and its variance. We used alpha = 0.05
to interpret statistical significance (i.e. 95% confidence
interval excludes the null), and considered a change in
cost of 10% (compared to the variable’s reference group)
to be economically relevant. To further investigate the
relation between cost and death (by comorbid condition)
we also present a Cox proportional hazards model ana-
lysis of the risk of death. We used a complete case ana-
lysis. We used SAS (SAS version 6.12 and 8.2, Cary NC)
and Stata 9.2 (College Station, Texas, USA) for all
analyses.
Results
Among 519,383 adults aged 18 years and older, we
found 10,265 with a diagnosis of heart failure, and 8,291
of these had an echocardiogram. Our analysis dataset
included the 4,696 (of 8,291) patients who had at least
one year of health plan membership and pharmacy
coverage before their echocardiogram; 381 (8% of 4,696)
had new-onset (incident) heart failure. Table 2 shows the
baseline characteristics for the sample, stratified by
whether patients had incident or prevalent disease.
Patients with prevalent heart failure were older, and had
a greater comorbidity load (with the exception of aortic
valvular disease) than incident patients.
Table 3 shows the independent contribution (and pre-
cision estimates) of demographic, clinical and comorbid
factors to total monthly cost of care. The estimates are
expressed as relative percent change from the omitted
group; negative percents represent lower costs compared
to the omitted group. Several diseases were associated
with significantly higher and economically relevant cost
changes, including atrial fibrillation (15% higher), coron-
ary artery disease (14% higher), chronic lung disease
(29% higher), depression (36% higher), diabetes (38%
higher) and hyperlipidemia (21% higher). With the ex-
ception of hyperlipidemia, patients with these diseases
had not only higher costs but also a higher death rate.
Some covariables showed significant, economically
relevant cost changes in an unexpected direction (i.e.
that patients with the factor had lower costs) including
older age, anemia (defined as hemoglobin <11mg/dl
Table 2 Characteristics of the population at baseline
(most recent values, up to 3 years prior to index date) by





Demographics n (%) n (%) Total N
Age
20-59 years 777 (18.01%) 98 (25.72%) 875
60-64 415 (9.62%) 28 (7.35%) 443
65-69 512 (11.87%) 39 (10.24%) 551
70-74 607 (14.07%) 60 (15.75%) 667
75-79 735 (17.03%) 57 (14.96%) 792
80-84 630 (14.60%) 59 (15.49%) 689
85 years and over 639 (14.81%) 40 (10.50%) 679
Gender
male 2061 (47.76%) 223 (58.53%) 2284
female 2254 (52.24%) 158 (41.47%) 2412
Race
white 4074 (94.41%) 365 (95.80%) 4539
non-white 241 (5.59%) 16 (4.20%) 257
Clinical findings and measurements
BMI (kg/m2)
<25 1034 (23.96%) 83 (21.78%) 1117
25-34 2331 (54.02%) 219 (57.48%) 2550
>=35 950 (22.02%) 79 (20.73%) 1029
Smoking Status
current smoker 418 (9.69%) 38 (9.97%) 456
never or former smoker 3897 (90.31%) 343 (90.03%) 4240
Systolic blood pressure (mm/hg)
<120 1267 (29.36%) 126 (33.07%) 1393
120-140 1637 (37.94%) 149 (39.11%) 1786
>140 1411 (32.70%) 106 (27.82%) 1517
Hemoglobin
<11gm/dl 466 (10.80%) 42 (11.02%) 508
>= 11gm/dl 3849 (89.20%) 339 (88.98%) 4188
Renal function* (ml/min/1.73m2)
>=60 2389 (55.37%) 261 (68.50%) 2650
45-60 972 (22.53%) 64 (16.80%) 1036
30-45 671 (15.55%) 35 (9.19%) 706
<30 283 (6.56%) 21 (5.51%) 304
Ejection fraction on echocardiogram(%)
>65 353 (8.18%) 18 (4.72%) 371
51-65 2331 (54.02%) 169 (44.36%) 2500
41-50 533 (12.35%) 60 (15.75%) 593
31-40 488 (11.31%) 62 (16.27%) 550
21-30 417 (9.66%) 55 (14.44%) 472
1-20 193 (4.47%) 17 (4.46%) 210
Posterior wall thickness on echocardiogram (mm)
<11 1763 (40.86%) 154 (40.42%) 1917
Table 2 Characteristics of the population at baseline
(most recent values, up to 3 years prior to index date) by
prevalent and incident cohort (Continued)
>=11 2552 (59.14%) 227 (59.58%) 2779
Comorbid diagnoses
Atrial fibrillation
yes 1603 (37.15%) 123 (32.28%) 1726
no 2712 (62.85%) 258 (67.72%) 2970
Aortic valvular disease
yes 1354 (31.38%) 141 (37.01%) 1495
no 2961 (68.62%) 240 (62.99%) 3201
Coronary artery disease
yes 2224 (51.54%) 178 (46.72%) 2402
no 2091 (48.46%) 203 (53.28%) 2294
Chronic lung disease
yes 2002 (46.40%) 141 (37.01%) 2143
no 2313 (53.60%) 240 (62.99%) 2553
Depression
yes 961 (22.27%) 81 (21.26%) 1042
no 3354 (77.73%) 300 (78.74%) 3654
Diabetes
yes 1480 (34.30%) 102 (26.77%) 1582
no 2835 (65.70%) 279 (73.23%) 3114
Hypothyroidism
yes 726 (16.83%) 47 (12.34%) 773
no 3589 (83.17%) 334 (87.66%) 3923
Hyperlipidemia
yes 2010 (46.58%) 181 (47.51%) 2191
no 2305 (53.42%) 200 (52.49%) 2505
Peripheral vascular disease
yes 703 (16.29%) 49 (12.86%) 752
no 3612 (83.71%) 332 (87.14%) 3944
Stroke
yes 474 (10.98%) 37 (9.71%) 511
no 3841 (89.02%) 344 (90.29%) 4185
Transient ischemic attack
yes 298 (6.91%) 23 (6.04%) 321
no 4017 (93.09%) 358 (93.96%) 4375
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hazard ratio (HR) on mortality in Table 3 reveals that in
each case the patients are significantly more likely to die
in the presence of these variables. For example, com-
pared with the oldest age cohort (85 years and above)
patients aged 20–59 years had a HR of 0.38 (95% CI
0.27 to 0.53); patients with anemia were twice as likely
to die (HR = 2.08, 95% CI 1.70 to 2.53); and compared
with the worst level of ejection fraction, patients with
normal ejection fraction (51% – 65%) were less likely to
Table 3 Demographic, clinical and comorbid factors contribution to cost of care
Adjusted % change in costs over
12 months post-index date:
All Patients (Accounting for
loss to follow-up,
costs recorded as zero post death)
Adjusted change in costs over
12 months post-index date:
Survivors (Includes patients
who did not die;
Accounting for loss to follow-up)
Adjusted Hazard Ratio
(HR) of death
over 12 months post-index
Demographics
Age (years) estimate CI estimate CI HR CI
20-59 81.70% (43.8% to 119.7%) 24.62% (4.04% to 45.20%) 0.38 (0.27 to 0.53)
60-64 85.60% (44.8% to 126.3%) 31.74% (9.90% to 53.58%) 0.37 (0.25 to 0.55)
65-69 95.40% (55.5% to 135.3%) 38.45% (16.91% to 59.98%) 0.38 (0.26 to 0.54)
70-74 75.80% (41.9% to 109.7%) 30.56% (11.53% to 49.60%) 0.48 (0.36 to 0.64)
75-79 69.60% (38.4% to 100.8%) 30.10% (12.24% to 47.96%) 0.54 (0.42 to 0.71)
80-84 24.90% (0.4% to 49.4%) 19.94% (2.96% to 26.93%) 0.81 (0.64 to 1.02)
85 years and over (reference)
Gender
male (reference)
Female −14.80% (−24.0% to −5.6%) −12.74% (20.21% to −5.27%) 1.09 (0.92 to 1.30)
Race
white (reference)
non-white −0.10% (−22.1% to 21.9%) 3.48% (−14.58% to 21.54%) 1.33 (0.90 to 1.97)
Clinical findings and measurements
BMI (kg/m2)
<25 −11.00% (−26.7% to 4.6%) 13.16% (−2.11% to 28.43%) 1.78 (1.31 to 2.42)
25-34 −0.40% (−13.4% to 12.6%) 4.52% (−6.61% to 15.66%) 1.24 (0.94 to 1.63)
>=35 (reference)
Smoking Status
current smoker −24.80% (−37.9% to −11.8%) −21.58% (−32.74% to −10.41%) 1.28 (0.96 to 1.70)
never or former smoker (reference)
Systolic blood pressure (mm/hg)
<120 −8.00% (−20.3% to4.3%) 4.29% (−6.38% to 14.97%) 1.41 (1.14 to 1.74)
120-140 −10.10% (−20.5% to 0.2%) −2.40% (−11.08% to 6.29%) 1.26 (1.03 to 1.55)
>140 (reference)
Hemoglobin
<11gm/dl −20.10% (−36.7% to −3.6%) 33.27% (14.18% to 52.37%) 2.08 (1.70 to 2.53)
>= 11gm/dl (reference)
Renal function* (ml/min/1.73m2)
>=60 24.60% (−10.1% to 59.4%) −44.73% (−54.85% to −34.61%) 0.35 (0.27 to 0.45)





















Table 3 Demographic, clinical and comorbid factors contribution to cost of care (Continued)
30-45 24.70% (−12.8% to 62.1%) −31.49% (−44.97% to −18.01%) 0.57 (0.44 to 0.74)
<30 (reference)
Ejection fraction on echocardiogram(%)
>65 52.70% (1.5% to 103.4%) −3.00% (−26.81% to 20.81%) 0.43 (0.29 to 0.64)
51-65 50.70% (7.1% to 94.3%) −15.37% (−33.47% to 2.74%) 0.36 (0.27 to 0.49)
41-50 44.70% (0.3% to 89.0%) −14.80% (−34.20% to 4.60%) 0.39 (0.27 to 0.56)
31-40 47.10% (2.1% to 92.0%) −16.09% (−35.00% to 2.82%) 0.37 (0.26 to 0.53)
21-30 50.50% (4.3% to 96.8%) −5.38% (−26.83% to 16.07%) 0.44 (0.31 to 0.64)
1-20 (reference)
Posterior wall thickness on echocardiogram (mm)
<11 9.70% (−2.0% to 21.4%) 9.83% (69.90% to 18.96%) 1.10 (0.92 to 1.30)
>=11 (reference)
Comorbid diagnoses
Atrial fibrillation yes 15.30% (3.1% to 27.6%) 26.75% (16.72% to 36.79%) 1.08 (0.91 to 1.27)
no (reference)
Aortic valvular disease yes 0.40% (−10.5% to 11.3%) 9.25% (35.73% to 18.14%) 1.22 (1.03 to 1.44)
no (reference)
Coronary artery disease yes 13.90% (1.9% to 26.0%) 19.86% (10.19% to 29.53%) 1.09 (0.91 to 1.31)
no (reference)
Chronic lung disease yes 29.20% (16.3% to 42.0%) 44.95% (33.82% to 56.08%) 1.25 (1.06 to 1.47)
no (reference)
Depression yes 36.20% (18.6% to 53.8%) 64.00% (48.85% to 79.16%) 1.31 (1.08 to 1.58)
no (reference)
Diabetes yes 37.80% (22.5% to 53.0%) 64.82% (51.37% to 78.26%) 1.38 (1.16 to 1.65)
no (reference)
Hypothyroidism yes 1.40% (−13.1% to 15.8%) 21.20% (9.36% to 33.05%) 1.25 (1.02 to 1.52)
no (reference)
Hyperlipidemia yes 21.40% (8.4% to 34.4%) 14.35% (5.11% to 23.60%) 0.87 (0.73 to 1.04)
no (reference)
Peripheral vascular disease yes 13.20% (−4.0% to 30.3%) 37.31% (23.46% to 51.16%) 1.33 (1.10 to 1.62)
no (reference)
Stroke yes −0.80% (−19.0% to 17.4%) 19.08% (4.99% to 33.16%) 1.37 (1.10 to 1.71)
no (reference)
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our cost analysis to those patients who survived the en-
tire 12 month period we found cost changes in the
expected direction for patients with anemia (33.27%
higher, 95% CI 14.18% to 52.37%) and ejection fraction
(for example, patients with normal ejection fraction had
costs 15% lower (95% CI −33.47% to 2.74%) compared
with those who had the lowest level of ejection fraction).
Patients at younger ages were still found to be signifi-
cantly more costly even in the survivors-only cost
analysis.
We undertook an exploratory analysis (data not
shown) comparing relative changes in average monthly
costs by incident and prevalent patients (separately). We
found that ejection fraction and coronary artery disease
switched signs (e.g. from higher cost to lower cost) be-
tween incident and prevalent patients. Among prevalent
patients, a normal ejection fraction (51% to 65%) was
associated with higher costs (71%; 95% CI, 26% to 133%)
compared with the worst ejection fraction, but the op-
posite held for incident patients (−54%; 95% CI, -76% to
−13%). For coronary artery disease, incident patients had
lower costs (−40%; 95% CI −59.2% to 11.2%), while
prevalent patients had costs that were 20% higher (95%
CI 7.7% to 34.5%).
Discussion
Several diseases were associated with significantly higher
and economically relevant cost changes, including atrial
fibrillation, coronary artery disease, chronic lung disease,
depression, diabetes and hyperlipidemia. Since the pres-
ence of these factors lead to higher resource utilization
they are logical candidates for inclusion in risk stratifica-
tion selection processes for care management programs
and for clinical attention in these programs. Some of our
findings were counterintuitive in that patients with
advanced age, worse ejection fraction and anemia had
lower costs. These findings are surprising, but for
anemia and ejection fraction are probably best explained
by the greater risk of death. Patients with worse ejection
fraction and anemia were less costly because they died at
a higher rate. Like the other comorbid conditions listed
above, these two factors are also logical candidates for
risk selection and management. Why older patients have
lower costs is not clear from our analysis. One potential
explanation is a survivor effect.
Our finding that patients with certain conditions have
lower costs has implications for research into the burden
of disease. One implication is that in a disease like heart
failure where patients die at a high rate, using cost of
care as an outcome cannot capture all clinically mean-
ingful events (e.g. death), and so fails to synthesize in a
way that may matter to patients, clinicians, payers and
policy makers. When investigators are interested infollowing costs for a cohort of patients, costs after a pa-
tient dies are recorded as zero, because that patient’s
health care costs are fully known (zero) after death. This
practice accurately reflects the real costs of care for a co-
hort over time, but may not do so in a way that is mean-
ingful for all applications. For example, since physicians
obviously no longer provide care to patients following
death, their interest in the cost of patient care ceases.
Our work offers a descriptive solution by presenting cost
and death findings in a way that allows the reader to
examine them in parallel. Using a survivors-only cost
analysis as an adjunct is one way to illustrate how bur-
den of illness changes in the presence of comorbidities -
without the selection bias introduced by death. But this
solution is not completely satisfactory because it may
not yield cost estimates that are useful for a full eco-
nomic evaluation because patients who die are an im-
portant part of the cost function.
Work in other areas has shown that focus on incident
versus prevalent patients is a key to differentiating
patients’ risk profiles; [8] our exploratory analysis sug-
gests that further work comparing incident and preva-
lent heart failure patients may usefully discriminate
those at risk of high cost. Specifically, patients with inci-
dent heart failure and low ejection fractions (< 20%) had
higher costs than patients with incident heart failure and
higher ejection fractions, but opposite findings were
observed for the full cohort of prevalent patients. The
explanation for this discrepancy may lie in the relatively
high procedural costs surrounding events that led to the
heart failure diagnosis. For example, a patient who has
an acute myocardial infarction may undergo a workup
that included an echocardiogram, leading to an incident
diagnosis of heart failure. Acute events, such as myocar-
dial infarction may also be associated with other expen-
sive interventions including coronary artery bypass
surgery or angiography, thus leading to significant costs
among incident patients. High cost events may be asso-
ciated with more severe decompensation as well, reflect-
ing the expense of lower ejection fractions among
incident patients compared with those of higher ejection
fractions. Another explanation may involve the severity
of the initial diagnosis with intense early management of
those with the poorest ejection fraction, followed by a
higher death rate as time passes. However, these ex-
ploratory findings may also have been due to chance, as
we made multiple comparisons with these groupings.
Our findings are similar to recent work by Dunlay et
al. [15]. who investigated the lifetime cost of care in
patients with incident heart failure. They showed, for ex-
ample, that diabetes and preserved ejection fraction were
associated with higher costs. However, they found that
anemia was associated with 10% higher costs, while our
study showed anemia to be associated with 20% lower
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tion selection differences, since we examined incident
and prevalent patients and followed them for 12 months.
We did find comparable results (anemia associated with
a 33% increase in costs) when our analysis was restricted
to patients who survived.
Our study was limited to a single site and to patients
who were members of an HMO. But the integrated care
at the HMO allowed us to track comprehensive
utilization across time and to examine demographic and
clinical findings for these patients. Although the cost
structure in the HMO is likely not completely transfer-
able, investigators hypothesize that the ratio of costs, like
those we presented in this paper, are more likely to
meaningfully compare across systems of health care
[16]. Another limitation to our analysis is that due to
sample size considerations we did not evaluate inter-
action effects, for example anemia and chronic kidney
disease. In the case of economically meaningful inter-
action between factors, we may have over- or under-
estimated the true contribution of these factors to cost
of care.
We used the receipt of an echocardiogram as an index
date to have a common event in a patient’s natural his-
tory of heart failure. But using the date of an echocar-
diogram meant that the patients were medically
supervised more closely; the absolute estimates of one
year costs may be inflated when compared with other
points in the natural history of heart failure.
Conclusion
In conclusion, previous studies of the costs related to
heart failure have largely focused on the overall burden
of disease [2,3]. Some analyses that have examined the
contribution of comorbid conditions were limited by ac-
cess to clinical information [17]. Our study examines the
question of burden in heart failure from a different per-
spective and has shown that 1) cost patterns may differ
for newly diagnosed and prevalent patients, and 2) that
several conditions (atrial fibrillation, coronary artery dis-
ease, chronic lung disease, depression, diabetes and
hyperlipidemia) contribute independently to the cost of
care in heart failure. These comorbid conditions may be
important targets for disease management efforts. Fur-
ther research could be usefully aimed toward a better
understanding of how to best report the results of eco-
nomic studies in conditions with a high death rate, and
toward understanding reasons for the cost differences
between patients with incident and prevalent disease.
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